ArticleLife (Basel, Switzerland)2026
Time in Range as a Marker of Concurrent Glycemic and Lipid Improvement in Adults with Type 2 Diabetes: A Real-World Retrospective Pre-Post Study.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study aims to evaluate whether continuous glucose monitoring (CGM)-derived time in range (TIR) attainment is associated with concurrent improvements in glycemic control and lipid profiles among adults with type 2 diabetes mellitus (T2DM). In this retrospective, single-arm pre-post study, 542 adults with T2DM who underwent intermittently scanned CGM for 12 weeks were analyzed. Glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were compared before and after CGM use. Participants were stratified by TIR into low (<50%), intermediate (50-70%), and target (>70%) groups. Overall, HbA1c decreased from 8.12% to 7.49% and FPG from 153.35 to 136.70 mg/dL (both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.